Down-regulation of  LAPTM5  in human cancer cells

Michelle Nuylan; Tatsuyuki Kawano; Johji Inazawa; Jun Inoue

doi:10.18632/oncotarget.8614

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Down-regulation of LAPTM5 in human cancer cells

Michelle Nuylan, Tatsuyuki Kawano, Johji Inazawa and Jun Inoue _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:28320-28328. https://doi.org/10.18632/oncotarget.8614

Metrics: PDF 1768 views | HTML 2511 views | ?

Abstract

Michelle Nuylan1, Tatsuyuki Kawano2, Johji Inazawa1,3,4, Jun Inoue1,4

1Department of Molecular Cytogenetics, Medical Research Institute and Graduate School of Medical and Dental Science, Tokyo Medical and Dental University, Tokyo, Japan

2Department of Esophageal and General Surgery, Graduate School, Tokyo Medical and Dental University, Tokyo, Japan

3Department of Genome Medicine, Hard Tissue Genome Research Center, Tokyo Medical and Dental University, Tokyo, Japan

4Bioresource Research Center, Tokyo Medical and Dental University, Tokyo, Japan

Correspondence to:

Jun Inoue, email: [email protected]

Johji Inazawa, email: [email protected]

Keywords: LAPTM5, ESCC, tumor suppressor genes, lysosomes, cell death

Received: November 26, 2015 Accepted: March 18, 2016 Published: April 6, 2016

ABSTRACT

Lysosomal-associated protein multispanning transmembrane 5 (LAPTM5) is a membrane protein that localizes to intracellular vesicles. It has been previously demonstrated that LAPTM5 expression level is decreased in neuroblastoma (NB) cells, and excessive accumulation of LAPTM5 was shown to induce lysosomal cell death in these cells. However, the pathological expression and role of LAPTM5 in other types of human cancers are largely unknown. Here, we found that LAPTM5 mRNA level is frequently decreased in various cancer cell lines, and its low expression in patients with esophageal squamous cell carcinoma (ESCC) and non-small cell lung cancer (NSCLC) was significantly correlated with poor prognosis. Furthermore, we showed that overexpression of LAPTM5 in several cancer cells induces lysosomal cell death due to lysosomal destabilization, indicated by leakage of lysosomal cathepsin D into the cytosol as well as impairment of autophagy. These findings suggest that the inactivation of LAPTM5 may contribute to tumorigenesis in a subset of human cancers.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8614

Publication Alerts

Research Papers:

Down-regulation of LAPTM5 in human cancer cells

Abstract